Alex Y. Nie, an associate with Foley & Lardner LLP, is a member of the firm's Chemical, Biotechnology & Pharmaceutical and Electronics Practices and the Life Sciences Industry Team. Dr. Nie's practice entails the procurement of patents and related counseling in matters in life science and information technology. With respect to life science, Dr. Nie's focus is on personalized medicine, computational biology and chemistry, in vitro diagnostics and stem cell technology in addition to conventional biotechnology and pharmaceuticals. Within information technology, Dr. Nie's practice relates to general software and hardware, such as those involving machine learning methods, encryption technologies, mobile platform and digital circuit design. Prior to his legal career, Dr. Nie was a senior scientist with Johnson & Johnson Pharmaceutical R&D, L.L.C. During his seven year-tenure at the company, Dr. Nie developed new biomarkers for drug safety evaluation using genomics, machine learning and statistical approaches. He was a Johnson & Johnson representative to the Critical Path Institute, an industry-wide collaborative effort to improve the drug approval process. Dr. Nie earned his J.D. degree from Rutgers School of Law - Newark. He is a graduate of Rutgers - New Brunswick (Ph.D. in biochemistry and M.S. in computer science). Dr. Nie received an M.S. degree in molecular biology from the University of Science & Technology of China and a B.S. degree in biochemistry from Wuhan University. Dr. Nie has published 25 peer-reviewed scientific articles and two book chapters. He received an NIH grant and has served as a committee member for various scientific organizations, including the International Life Science Institute/Health and Environment Sciences Institute (ILSI-HESI), the Critical Path Institute, and FDA's HL7/CDISC/I3C Pharmacogenomics Data Standards Committee. He was a session chairman and invited speaker at the Drug Information Association's 2006 annual conference in Paris. Dr. Nie is a member of the State Bar of California, and is registered to practice before the United States Patent and Trademark Office. Dr. Nie's selected publications include: · Nie, "USPTO's 2010 - 2015 Strategic Plan," published in Foley & Lardner LLP Fall 2010 edition of Legal News: China Quarterly Newsletter, Eye on China (October 2010) · Best, Carsten and Nie, "Ninth Circuit," Ch. 10 in Patent Obviousness in the Wake of KSR International Co. v. Teleflex Inc., (Paul. M. Rivard and Alan Gardner, eds., 2010) · Wright Bonnilla, Brinckerhoff, Konski and Nie, "Patent Eligibility of Personalized Medicine Method Claims Confirmed by Federal Circuit in Prometheus Labs., Inc. v. Mayo," published in Foley & Lardner LLP Legal News Alert: Biotechnology & Pharmaceutical (September 2009) · Konski, Brinckenhoff and Nie, "Genes Under the Microscope - Novel or Not?" published in Intellectual Property Today (July 2009) · Nie, "Introduction to the U.S. Patent Reform Act of 2009," published in Foley & Lardner LLP Summer 2009 Eye on China Newsletter (August 2009) · Zhao, Nie and Tang, "PRC Supreme People's Court Patent Infringement Enforcement Guidance: The "Draft" Published for Comments by the Patent Community," published in Foley & Lardner LLP Legal News Alert: China (July 2009) · Fielden and Nie et al., "Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat," published in Toxicological Sciences (vol 103, pages 28-34, 2008) · Nie et al., "Predictive Toxicogenomics Approaches Reveal Underlying Molecular Mechanisms of Nongenotoxic Carcinogenicity," published in Molecular Carcinogenesis (vol 45, pages 914-933, 2006) · Nie, McMillian and Lord, "Toxicogenomics in Drug Safety Evaluation: Bridging Drug Discovery and Development," published in Carmen and Hardiman eds. Biochips as Pathways to Drug Discovery. Florida: Taylor & Francis Group (pages 69-96, 2006) Speeches and Presentations: · "U.S. Perspective of Patent Enforcement in China," 2009 U.S.-China Legal Exchange, Los Angeles, California (October 12, 2009) · "An Analysis of the Characteristics of Licensed Clean Tech Patents from Publicly Announced Commercialization Deals," the 5th International Congress of Nano-Bio Clean Tech 2008 conference, San Francisco, California (October 27-30, 2008) · "Preparing the Critical Path to Acceptance of Toxicogenomic Data in Drug Safety Evaluation," the 2007 Joint Statistics Meeting, Salt Lake City, Utah (July 26 - August 2, 2007) · "Bioinformatics Lighting a New Path to Better Drug Development," the Drug Information Association 18th Annual EuroMeeting, Paris, France (March 6-8, 2006) |